Simplicity Solutions LLC Reduces Stock Position in Genmab A/S (NASDAQ:GMAB)

Simplicity Solutions LLC reduced its holdings in Genmab A/S (NASDAQ:GMAB) by 7.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,305 shares of the company’s stock after selling 1,669 shares during the period. Simplicity Solutions LLC’s holdings in Genmab A/S were worth $710,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. First Manhattan Co. bought a new stake in shares of Genmab A/S in the 4th quarter worth about $26,000. Headlands Technologies LLC bought a new stake in shares of Genmab A/S in the 3rd quarter worth about $27,000. Pinnacle Bancorp Inc. lifted its holdings in shares of Genmab A/S by 315.8% in the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after acquiring an additional 638 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of Genmab A/S in the 3rd quarter worth about $37,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Genmab A/S by 86.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after acquiring an additional 498 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $28.53 on Thursday. Genmab A/S has a one year low of $26.32 and a one year high of $42.72. The firm has a market cap of $18.86 billion, a P/E ratio of 29.72, a P/E/G ratio of 2.12 and a beta of 0.99. The firm has a 50-day simple moving average of $29.35 and a 200-day simple moving average of $30.35.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. The firm had revenue of $675.29 million for the quarter, compared to the consensus estimate of $678.14 million. On average, research analysts predict that Genmab A/S will post 1.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on GMAB shares. BMO Capital Markets upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. Citigroup lowered shares of Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Truist Financial reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, April 4th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Hold” and a consensus price target of $48.50.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.